Berzosertib is a first in class, selective and potent inhibitor of ATR and several in vitro and in vivo preclinical studies have shown the radiation sensitising effects of ATR inhibition including synergy with berzosertib in oesophageal cancer models [5–7]. The gene discussed is ATR; the disease is carcinoma of esophagus.